[ACHN] Achillion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.38 Change: 0.39 (9.77%)
Ext. hours: Change: 0 (0%)

chart ACHN

Refresh chart

Strongest Trends Summary For ACHN

ACHN is in the long-term down -79% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Fundamental Ratios
Shares Outstanding EPS-0.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-9
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.83% ROE-27.14% ROI
Current Ratio19.64 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.96 M Cash From Investing Activities-148.58 M Cash From Operating Activities-17.32 M Gross Profit
Net Profit-19.26 M Operating Profit-19.4 M Total Assets279.42 M Total Current Assets255.58 M
Total Current Liabilities13.01 M Total Debt610 K Total Liabilities13.41 M Total Revenue
Technical Data
High 52 week5.15 Low 52 week2.65 Last close3.1 Last change1.31%
RSI20.21 Average true range0.12 Beta0.8 Volume2.41 M
Simple moving average 20 days-9.36% Simple moving average 50 days-12.63% Simple moving average 200 days-13.92%
Performance Data
Performance Week-1.27% Performance Month-10.92% Performance Quart-26.37% Performance Half6.9%
Performance Year-26.01% Performance Year-to-date7.64% Volatility daily2.03% Volatility weekly4.55%
Volatility monthly9.32% Volatility yearly32.3% Relative Volume236.65% Average Volume1.22 M
New High New Low

News

2019-11-11 07:30:00 | Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks

2019-11-07 16:55:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout

2019-11-07 09:00:00 | Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders - CISN, ACHN, VSI

2019-11-07 07:30:00 | Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-06 14:36:44 | Here is What Hedge Funds Think About Achillion Pharmaceuticals, Inc. ACHN

2019-11-06 13:35:00 | INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Transaction

2019-11-06 10:45:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - AYR, WLH, ACHN

2019-11-06 09:07:20 | Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

2019-11-05 14:35:00 | STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding Buyout

2019-11-04 16:04:44 | Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – LPT, CISN, IPHS, ACHN

2019-11-04 14:55:00 | Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

2019-11-01 18:00:00 | STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Buy Out

2019-11-01 14:10:00 | Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – RARX, ACHN, IPHS, CISN

2019-10-30 15:45:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of the Following Investigation

2019-10-30 10:43:57 | Healthcare ETFs Win in October: Here's Why

2019-10-29 15:02:39 | SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations

2019-10-28 12:30:45 | MERGER ALERT – ACHN, RARX, and IPHS: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies

2019-10-24 13:59:52 | SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions

2019-10-24 11:26:00 | ACHILLION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Achillion Pharmaceuticals, Inc. - ACHN

2019-10-24 11:09:03 | The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

2019-10-24 09:35:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CISN, IPHS, ACHN

2019-10-23 16:35:22 | MERGER ALERT – ACHN, JAG, and ROAN: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies

2019-10-23 14:00:00 | ACHN, ROAN, VSI: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger

2019-10-23 11:26:03 | Alexion ALXN Beats on Q3 Earnings, Lifts 2019 Guidance

2019-10-23 10:10:02 | Biotech ETFs Surge on a Flurry of Positive News

2019-10-23 09:45:01 | Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

2019-10-22 15:07:00 | Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – IPHS, ACHN, RARX, TSG

2019-10-21 09:33:01 | Alexion Gets FDA Approval for Label Expansion of Ultomiris

2019-10-19 10:30:00 | INVESTOR ALERT: Monteverde & Associates PC Is Investingating The Merger

2019-10-18 16:50:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?

2019-10-18 12:00:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN

2019-10-18 07:04:11 | Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

2019-10-17 12:22:00 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Achillion Pharmaceuticals, Inc. NASDAQ: ACHN on Behalf of Achillion Shareholders and Encourages Achillion Investors to Contact the Firm

2019-10-17 07:39:15 | The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO

2019-10-16 21:35:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Achillion Pharmaceuticals, Inc. NASDAQ GS: ACHN

2019-10-16 15:05:59 | Montco biotech firm sold for $930M, shares soar

2019-10-16 12:00:00 | ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2019-10-16 11:43:56 | Alexion makes $930M acquisition in bid to bolster blockbuster drug

2019-10-16 11:38:07 | ACHILLION MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Achillion Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACHN

2019-10-16 11:15:00 | Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion

2019-10-16 10:44:00 | Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc.

2019-10-16 08:50:00 | Achillion ACHN Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fair Deal?

2019-10-16 07:25:06 | Alexion To Acquire Achillion Pharma For $930M

2019-10-16 07:15:00 | Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal

2019-10-16 06:41:53 | Drugmaker Alexion to buy biotech Achillion in $930 mln deal

2019-10-16 06:30:00 | Alexion to Acquire Achillion

2019-10-16 06:00:00 | Alexion Pharmaceuticals to Acquire Achillion in $930 Million Deal

2019-09-26 11:32:03 | Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN